HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

1.Industry viewpoints:<ul>
<li>Recently, the National Medical Products Administration has released a new policy (draft version) about the online drug sales.</li>
<li>Vaccine is a hot topic in 2020, so let’s talk about vaccine.</li>
<li>The upsurge in the application of AI in medical imaging in China provides a new direction for the development, which may be the most promising field for China to surpass foreign countries.</li>
</ul>2. Company news:News about the updated progress of new drugs and the marketing approval of new products from <a href="https://www.smartkarma.com/entities/betta-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:25883:1" rel="noopener">Betta Pharmaceuticals (300558 CH)</a>, <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a> , Kangpu Biopharmaceuticals, and <a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech (2500 HK).</a>3. Market review:Last week, stock price for healthcare sector in A share decreased 1.43%, while CSI 300 increased 1.78% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1.Industry viewpoints:
Recently, the National Medical Products Administration has released a new policy (draft version) about the online drug sales.
Vaccine is a hot topic in 2020, so let’s talk about vaccine.
The upsurge in the application of AI in medical imaging in China provides a new direction for the development, which may be the most promising field for China to surpass foreign countries.
2. Company news:News about the updated progress of new drugs and the marketing approval of new products from Betta Pharmaceuticals (300558 CH), BeiGene Ltd (6160 HK) , Kangpu Biopharmaceuticals, and Venus MedTech (2500 HK).3. Market review:Last week, stock price for healthcare sector in A share decreased 1.43%, while CSI 300 increased 1.78% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:
<ul>
<li>As the population ages, it is expected that the domestic dental prosthesis market has a great potential for development.</li>
<li>In the future, the market of China medical beauty has a broad space for growth.</li>
<li>POCT (point-of-care testing) has gained popularity in recent years and has become one of the fastest growing IVD tracks.</li>
</ul>
2. Company news:
News from <a href="https://www.smartkarma.com/entities/beigene-ltd" target="_blank" data-smartkarma-citation="entities:27352:1" rel="noopener">BeiGene Ltd (6160 HK)</a> , <a href="https://www.smartkarma.com/entities/shanghai-fosun-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:8045:1" rel="noopener">Shanghai Fosun Pharmaceutical (Group) (2196 HK)</a>, Aravive and <a href="https://www.smartkarma.com/entities/ping-an-healthcare-and-technology-company-limited" target="_blank" data-smartkarma-citation="entities:27008:1" rel="noopener">Ping An Healthcare and Technology Company Limited (1833 HK)</a> about the progress of new drugs, vaccine for COVID-19, new license agreement and the establishment of the Internet Eye Center.
3. Market review:
Last week, stock price for healthcare sector in A share decreased 1.23%, while CSI 300 decreased 0.59% over the same period of time. 
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints:

As the population ages, it is expected that the domestic dental prosthesis market has a great potential for development.
In the future, the market of China medical beauty has a broad space for growth.
POCT (point-of-care testing) has gained popularity in recent years and has become one of the fastest growing IVD tracks.

2. Company news:
News from BeiGene Ltd (6160 HK) , Shanghai Fosun Pharmaceutical (Group) (2196 HK), Aravive and Ping An Healthcare and Technology Company Limited (1833 HK) about the progress of new drugs, vaccine for COVID-19, new license agreement and the establishment of the Internet Eye Center.
3. Market review:
Last week, stock price for healthcare sector in A share decreased 1.23%, while CSI 300 decreased 0.59% over the same period of time. 
4. Risk Disclosure:
Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints: <ul>
<li>A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.</li>
<li>Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.</li>
<li>Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.</li>
</ul>2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

1. Industry viewpoints: 
A new policy was released to clarify the scope and price of medical insurance payments for online healthcare service, which help open up the market scale of digital healthcare business.
Currently, some of the so-called "innovative drugs" in China are still far from real innovation, such as the PD-1 market.
Polypeptide drugs account for a small share in the global biomedical market, but they are developing rapidly.
2. Company news:News from Wondfo Biotech, CSPC and Sino Biopharm about the new products for COVID-19 antigen tests, clinical progress on new category 1 drug and the new products that pass the consistency evaluation in China.3. Market review:Last week, stock price for healthcare sector in A share decreased 1.36%, while CSI 300 increased 4.05% over the same period of time.4. Risk Disclosure:Policy risk, R&amp;D risk, Company risk and COVID-19 risk.

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Last evening, the Hang Seng Indexes Company announced the launch of the Hang Seng TECH Index on 27 July. The new index will track the 30 largest technology companies listed in Hong Kong.The index universe covers Hong Kong-listed companies that have high business exposure to selected technology themes, including internet, fintech, cloud, e-commerce and digital activities. Eligible candidates are further screened by whether they operate via a technology-enabled platform, their research and development expenses to revenue ratio, and their revenue growth. After this screening, the top 30 stocks in terms of market capitalisation are selected as index constituents.Given the investor focus on technology names and the outperformance over the last few months and years, it is only a matter of time before ETFs and derivatives that track the new index are launched further driving up valuations and liquidity.The rise in liquidity on the index stocks and the launch of ETFs and derivatives will be a positive for <a href="https://www.smartkarma.com/entities/hong-kong-exchanges-clearing" target="_blank" data-smartkarma-citation="entities:490:1" rel="noopener">HKEX (388 HK)</a>.

Last evening, the Hang Seng Indexes Company announced the launch of the Hang Seng TECH Index on 27 July. The new index will track the 30 largest technology companies listed in Hong Kong.The index universe covers Hong Kong-listed companies that have high business exposure to selected technology themes, including internet, fintech, cloud, e-commerce and digital activities. Eligible candidates are further screened by whether they operate via a technology-enabled platform, their research and development expenses to revenue ratio, and their revenue growth. After this screening, the top 30 stocks in terms of market capitalisation are selected as index constituents.Given the investor focus on technology names and the outperformance over the last few months and years, it is only a matter of time before ETFs and derivatives that track the new index are launched further driving up valuations and liquidity.The rise in liquidity on the index stocks and the launch of ETFs and derivatives will be a positive for HKEX (388 HK). 

Hang Seng TECH Index - New Kid On The Block

Mark Artherton, CFA

Inteqres

We dissect the recent decline across Asia and emerging markets with the aim of identifying a few interesting areas for managers to utilise cash.   The suggestions are both short and long term.  This first note looks at the markets from a sectoral viewpoint.  We identify a few banks, healthcare and tech companies worthy of investor attention.

We dissect the recent decline across Asia and emerging markets with the aim of identifying a few interesting areas for managers to utilise cash.   The suggestions are both short and long term.  This first note looks at the markets from a sectoral viewpoint.  We identify a few banks, healthcare and tech companies worthy of investor attention.

Covid-19 - We Identify Some Opportunities in Markets - Inteqres Review

China

Ping An Healthcare and Technology Company Limited operates an online healthcare services platform in China, offering online consultations, hospital referrals, health management, and wellness services. The company provides a range of services including online diagnosis and treatment, health check-ups, and drug delivery through its mobile platform. It was founded in 2014 and is headquartered in Shanghai, China.

Ping An Healthcare and Technology (1833 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ping An Healthcare and Technology (1833 HK)

China Healthcare Weekly (Nov. 20)

The article summarized the new healthcare policy released, major industry viewpoints, company news and capital market review in China healthcare...

Xinyao (Criss) Wang

China Healthcare Weekly (Nov.13)

The article summarized the major industry viewpoints, company news and capital market review for China healthcare industry in the week of November...

Xinyao (Criss) Wang

China Healthcare Weekly (Nov.6)

This article summarized the new healthcare policy released in China, major industry viewpoints, company news and capital markets review for the...

Xinyao (Criss) Wang

Hang Seng TECH Index - New Kid On The Block

Last evening, the Hang Seng Indexes Company announced the launch of the Hang Seng TECH Index on 27 July. The new index will track the 30 largest...

Brian Freitas

Covid-19 - We Identify Some Opportunities in Markets - Inteqres Review

We dissect the recent decline across Asia and emerging markets with the aim of identifying a few interesting areas for managers to utilise cash. ...

Mark Artherton, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)